{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"163","value":"411"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Atezolizumab"}],"paramType":"MEAN","populationDescription":"PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.","reportingStatus":"POSTED","timeFrame":"0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour)","title":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter (μg/ mL)"}